Ranjeeta Sinvhal

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*

Kenneth B. Gordon, Mark Lebwohl, Kim Papp et al. · British Journal of Dermatology · 2021 · 99 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

Kim Papp, Mark Lebwohl, L. Puig et al. · British Journal of Dermatology · 2021 · 49 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +13

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up

Kim Papp, Andrew Blauvelt, L. Puig et al. · Journal of the American Academy of Dermatology · 2023 · 46 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15

Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials

Kenneth B. Gordon, Andrew Blauvelt, H. Bachelez et al. · Dermatology and Therapy · 2024 · 16 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16